Form D · Biotechnology
Jade Therapeutics, Inc.
Salt Lake City, X1 · CIK 0001591214
Offering snapshot reported Dec 31, 2014 · SEC filing
- Reported sold
- Yet to sell Offering amount: $800K
- Investors reported
- 0 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- Yet to occur As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Dec 31, 2014 | Initial | Yet to sell | No comparison | 0 | SEC filing |
| Nov 8, 2013 | Initial | Yet to sell | No comparison | 0 | SEC filing |
Offering details
- Securities
- Equity
- Exemptions
- 04
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-231146
Source: Form D, filed Dec 31, 2014. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Arthur Klausner | Director, Executive |
| Randall Olson | Director |
| Dinesh Patel | Director |
| Mary Jane Rafii | Director, Executive |
| Barbara Wirostko | Director, Executive |
Issuer details
Industry: Biotechnology (See others in industry)
Address:
675 Arapeen Dr., Suite 302
Salt Lake City, X1, 84108-1228
Salt Lake City, X1, 84108-1228